Skip to content

PTSD treatment dropout and nonresponse

TL;DR — Dropout and nonresponse are distinct: leaving treatment does not prove intolerance, and completing without adequate improvement is not dropout. A cross-disorder placebo-controlled CBT meta-analysis found PTSD-study dropout of 29.0% with CBT versus 17.2% with placebo, but that pooled paper included GAD, OCD, panic, social anxiety and acute stress disorder; only its PTSD stratum belongs here (Carpenter 2018, PMID 29451967). Routine-care estimates of 38–51% motivated a 916-veteran randomized CPT-versus-PE dropout analysis, which found dropout of 52.31% in PE against 45.77% in CPT, diverging after session 3 (Harper 2026, PMID 41926191). Trials should report timing, reasons, denominator and outcomes after dropout.

Definitions

Study dropout, treatment dropout, protocol noncompletion, loss to follow-up and missing outcome are separate events. Authors should define the last attended session and whether early responders who stopped are counted.

Why denominator matters

Per-protocol/completer effects answer what happened among completers; intention-to-treat estimates preserve randomization but still depend on missing-data assumptions. Neither alone measures delivered benefit.

Reasons

Scheduling, transport, childcare, work, relocation, cost, therapeutic mismatch, early improvement, symptom activation, adverse events and disengagement are not interchangeable, and trial reports rarely separate them: reviews of the PTSD evidence base and of CBT across disorders treat all-cause dropout as a single acceptability outcome rather than resolving its causes (Bisson 2021, PMID 34992739) (Cuijpers 2025, PMID 40238104). In a 157-RCT network and pairwise meta-analysis of 11,565 patients, all-cause dropout was the acceptability metric, and slightly more patients dropped out from TF-CBT than from non-trauma-focused interventions (RR 1.36, 95% CI 1.08–1.70, 22 comparisons), with no other between-intervention acceptability differences (Hoppen 2023, PMID 37141033).

Predictors

Baseline severity and demographics often show weak or inconsistent prediction. An individual-participant-data meta-analysis of 25 trauma-focused CBT trials (823 participants of 3,330 in 81 eligible studies) found 27% dropout overall, 23% among 581 civilians against 42% among 178 military personnel and veterans (RR 2.37 for military status), and a decreasing risk with advancing age (RR 0.98 per year) — but no strong pretreatment predictors beyond those (Wright 2024, PMID 39537555). A 19-study systematic review of veteran PTSD treatment retention likewise found only older age and higher treatment expectations associated with better retention at moderate quality of evidence; in five of six studies baseline PTSD severity was unrelated to retention, and more co-occurring psychiatric diagnoses were associated with better retention (Maglione 2022, PMID 34800059). Session-level change, alliance and avoidance sit closer to the event but are measured after randomization, so they carry post-randomization selection bias; in the CPT-versus-PE trial, slower symptom reduction predicted dropout in CPT but not in PE (Harper 2026, PMID 41926191).

Nonresponse

Response thresholds depend on measure and reliable-change rules. Some patients improve function without crossing a symptom threshold; others lose diagnosis but retain substantial burden.

Pooling warning

Mixed-anxiety attrition is not PTSD attrition. The Carpenter review is used only for its explicitly reported PTSD subgroup; its overall Hedges g=.56 is not presented as a PTSD effect (Carpenter 2018, PMID 29451967).

Design response

Pragmatic trials should collect minimal outcomes after discontinuation, competing reasons, treatment dose and patient choice; estimands should distinguish treatment-policy from hypothetical full-adherence effects.

Quantitative anchors

Measure Estimate Population/method Source
PTSD stratum in cross-disorder CBT review 29.0% CBT vs 17.2% placebo Do not report pooled anxiety effect as PTSD (Carpenter 2018, PMID 29451967)
CPT vs PE n=916 veterans Randomized timing/predictor analysis (Harper 2026, PMID 41926191)
Adult NMA 90 trials; n=6,560 Efficacy network; attrition affects certainty (Mavranezouli 2020, PMID 32063234)
Exposure review 65 articles; n=4,929 Moderators are study-level (McLean 2022, PMID 34954460)
CPT vs PE dropout 45.77% vs 52.31%; separation after session 3 n=916 US veterans (Harper 2026, PMID 41926191)
TF-CBT dropout, IPD 27% overall; 23% civilian vs 42% military (RR 2.37) 25 pooled trials; n=823 (Wright 2024, PMID 39537555)
TF-CBT vs non-TF acceptability RR 1.36 (95% CI 1.08–1.70) 157 RCTs; n=11,565; 22 comparisons (Hoppen 2023, PMID 37141033)
Veteran retention predictors older age, higher expectations (moderate QoE) 19 studies in 25 publications (Maglione 2022, PMID 34800059)

Evidence ledger

The ledger lists the live-retrieved records used to bound this page. Inclusion does not make every record equally probative; design, population and comparator remain decisive.

PMID Year Evidence contribution Scope caution
29451967 2018 Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials. Synthesis: preserve included-population and certainty limits
41926191 2026 Comparing dropout from cognitive processing therapy versus prolonged exposure: Results from a randomized clinical trial. PTSD-specific record; inspect design and population
40238104 2025 Cognitive Behavior Therapy for Mental Disorders in Adults: A Unified Series of Meta-Analyses. PTSD-specific record; inspect design and population
34992739 2021 Prevention and treatment of PTSD: the current evidence base. PTSD-specific record; inspect design and population
38173121 2024 EMDR v. other psychological therapies for PTSD: a systematic review and individual participant data meta-analysis. Synthesis: preserve included-population and certainty limits
24338345 2013 Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults. PTSD-specific record; inspect design and population
32813696 2020 Psychological and pharmacological interventions for posttraumatic stress disorder and comorbid mental health problems following complex traumatic events: Systematic review and component network meta-analysis. Synthesis: preserve included-population and certainty limits
41004137 2025 PTSD and complex PTSD, current treatments and debates: a review of reviews. Synthesis: preserve included-population and certainty limits
38652057 2024 State of the Science: Prolonged exposure therapy for the treatment of posttraumatic stress disorder. PTSD-specific record; inspect design and population
29252162 2018 Mindfulness-based treatments for posttraumatic stress disorder: a review of the treatment literature and neurobiological evidence. Synthesis: preserve included-population and certainty limits
38713560 2024 [MDMA-assisted therapy for PTSD]. PTSD-specific record; inspect design and population
36044299 2022 Psychotherapeutic interventions for childhood posttraumatic stress disorder: an update. PTSD-specific record; inspect design and population
34477098 2021 Comparing treatments for post-traumatic stress disorder - a systematic review. Synthesis: preserve included-population and certainty limits
38814110 2024 Interpersonal Psychotherapy for Posttraumatic Stress Disorder: A Critical Review of the Evidence. Synthesis: preserve included-population and certainty limits
29169664 2018 Long-term efficacy of psychotherapy for posttraumatic stress disorder: A meta-analysis of randomized controlled trials. Synthesis: preserve included-population and certainty limits
31797352 2019 Couple and family therapies for post-traumatic stress disorder (PTSD). PTSD-specific record; inspect design and population
12729679 2003 Posttraumatic stress disorder following medical illness and treatment. PTSD-specific record; inspect design and population
36595460 2024 A systematic review evaluating PTSD treatment effects on intermediate phenotypes of PTSD. Synthesis: preserve included-population and certainty limits
35700643 2022 Review of potential psychedelic treatments for PTSD. Synthesis: preserve included-population and certainty limits
15846661 2005 Psychological treatment of post-traumatic stress disorder (PTSD). PTSD-specific record; inspect design and population
38523454 2024 Systematic Review of Dispositional Mindfulness and Posttraumatic Stress Disorder Symptomology: A Targeted Examination of Avoidance. Synthesis: preserve included-population and certainty limits
17636720 2007 Psychological treatment of post-traumatic stress disorder (PTSD). PTSD-specific record; inspect design and population
34582228 2022 Treatment dropout among veterans and their families: Quantitative and qualitative findings. PTSD-specific record; inspect design and population
32063234 2020 Psychological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Synthesis: preserve included-population and certainty limits
32284821 2020 Psychological therapies for post-traumatic stress disorder in adults: systematic review and meta-analysis. Synthesis: preserve included-population and certainty limits
34954460 2022 Exposure therapy for PTSD: A meta-analysis. Synthesis: preserve included-population and certainty limits
32074319 2020 Drivers of Preference for Evidence-Based PTSD Treatment: A Qualitative Assessment. PTSD-specific qualitative evidence; preference is not efficacy
38590124 2024 Cognitive-behavioural conjoint therapy versus prolonged exposure for PTSD in military service members and veterans: results and lessons from a randomized controlled trial. PTSD-specific record; inspect design and population
39537555 2024 Predictors of study dropout in cognitive-behavioural therapy with a trauma focus for post-traumatic stress disorder in adults: An individual participant data meta-analysis. IPD; only 823 of 3,330 eligible participants pooled
34800059 2022 Effect of patient characteristics on posttraumatic stress disorder treatment retention among veterans: A systematic review. Narrative synthesis; definitions of dropout varied
37141033 2023 The efficacy and acceptability of psychological interventions for adult PTSD: A network and pairwise meta-analysis of randomized controlled trials. Synthesis: acceptability measured as all-cause dropout

Interpretation guardrails

  • Trauma exposure, post-traumatic symptoms, acute stress disorder, DSM-5 PTSD, ICD-11 PTSD and ICD-11 complex PTSD are not interchangeable populations.
  • A mixed-anxiety or transdiagnostic estimate is labelled as such; only a source’s PTSD stratum can be treated as a PTSD effect.
  • Comorbid depression is measured separately and cross-linked to the depression condition; it is not absorbed into PTSD.
  • Waitlist, treatment-as-usual, attention control and active treatment answer different causal questions.
  • Registration, statistical significance and diagnostic loss do not respectively prove completion, clinical importance or functional recovery.
  • This page synthesizes research and does not provide individual medical advice.

Minimum extraction frame for studies on this topic

Field What must be retained Why it changes interpretation
Diagnostic system DSM version, ICD version, full/subthreshold Case mix is not interchangeable
Diagnostic method Structured interview, clinician judgment, self-report cutoff Screening is not diagnosis
Index trauma Type, timing, repetition, direct/indirect/occupational Conditional risk and phenotype differ
Population Civilian, veteran, refugee, child/adolescent, mixed Transportability is empirical
Baseline severity Mean, SD, range and exclusion threshold Ceiling and floor effects alter change
CPTSD status ITQ/ICD-11 definition and DSO score Complexity cannot be inferred from trauma count
Comorbidity Depression, GAD, SUD, pain, TBI measured separately Shared symptoms can distort effects
Comparator Waitlist, usual care, attention, active treatment The estimand changes with comparator
Treatment dose Sessions offered/attended, duration, homework Assignment is not exposure
Outcome Symptoms, diagnosis, response, function, sleep Outcomes are not interchangeable
Time point End point and prespecified follow-up windows Acute benefit may not persist
Missing data Denominator, reasons, imputation and estimand Attrition can bias rank and magnitude
Adverse events Definitions, ascertainment and arm-level counts Absence of reporting is not absence of harm
Therapist/context Training, fidelity, allegiance, setting Delivery is part of the intervention
Funding/conflicts Sponsor role and analytic independence Especially material for proprietary packages

Claims this page does not make

  • It does not infer PTSD from trauma exposure alone.
  • It does not treat a self-report cutoff as equivalent to a structured diagnosis.
  • It does not convert a pooled anxiety-disorder effect into a PTSD effect.
  • It does not convert a depression outcome in a comorbid sample into a PTSD outcome.
  • It does not infer superiority from a statistically significant within-group change.
  • It does not infer equivalence from a non-significant between-group test.
  • It does not infer effectiveness from trial registration or mechanistic plausibility.
  • It does not assume military, civilian, refugee and pediatric estimates transport unchanged.
  • It does not average conflicting estimates that use different definitions.
  • It does not treat lack of adverse-event reporting as evidence of safety.

Evidence-updating triggers

Trigger Required response
New diagnostic revision Recalculate which populations prior estimates represent
New head-to-head RCT Compare against active treatment, not only waitlist
New individual-participant synthesis Revisit effect modifiers and transportability
Registry status change Verify results and linked publication before changing conclusions
Guideline update Separate evidence review from panel recommendation
Regulatory decision Record decision date and source; do not infer from efficacy papers
Safety signal Re-extract denominator, ascertainment and exposure time by arm
Contradictory replication Display estimates side by side; do not average definitions

Evidence updates should preserve the prior estimate and explain why the new study changes—or does not change—the inference.

Open questions

  • Which modifiable early-session signals predict avoidable dropout rather than administrative loss? (Harper 2026, PMID 41926191)
  • How should retention-adjusted benefit combine symptom change and treatment burden? (Mavranezouli 2020, PMID 32063234)
  • Do preference-matched assignments improve completion without sacrificing outcomes? (Etingen 2020, PMID 32074319)

References

  1. Carpenter JK, et al. Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials. Depress Anxiety. 2018;35(6):502-514. PMID 29451967
  2. Harper KL, et al. Comparing dropout from cognitive processing therapy versus prolonged exposure: Results from a randomized clinical trial. J Consult Clin Psychol. 2026;94(3):140-150. PMID 41926191
  3. Cuijpers P, et al. Cognitive Behavior Therapy for Mental Disorders in Adults: A Unified Series of Meta-Analyses. JAMA Psychiatry. 2025;82(6):563-571. PMID 40238104
  4. Bisson JI, et al. Prevention and treatment of PTSD: the current evidence base. Eur J Psychotraumatol. 2021;12(1):1824381. PMID 34992739
  5. Wright SL, et al. EMDR v. other psychological therapies for PTSD: a systematic review and individual participant data meta-analysis. Psychol Med. 2024;54(8):1580-1588. PMID 38173121
  6. Bisson JI, et al. Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults. Cochrane Database Syst Rev. 2013;2013(12):CD003388. PMID 24338345
  7. Coventry PA, et al. Psychological and pharmacological interventions for posttraumatic stress disorder and comorbid mental health problems following complex traumatic events: Systematic review and component network meta-analysis. PLoS Med. 2020;17(8):e1003262. PMID 32813696
  8. Billings J, et al. PTSD and complex PTSD, current treatments and debates: a review of reviews. Br Med Bull. 2025;156(1):ldaf015. PMID 41004137
  9. McLean CP, et al. State of the Science: Prolonged exposure therapy for the treatment of posttraumatic stress disorder. J Trauma Stress. 2024;37(4):535-550. PMID 38652057
  10. Boyd JE, et al. Mindfulness-based treatments for posttraumatic stress disorder: a review of the treatment literature and neurobiological evidence. J Psychiatry Neurosci. 2018;43(1):7-25. PMID 29252162
  11. Thorarinsdottir H, et al. [MDMA-assisted therapy for PTSD]. Laeknabladid. 2024;110(5):254-261. PMID 38713560
  12. Rossouw J, et al. Psychotherapeutic interventions for childhood posttraumatic stress disorder: an update. Curr Opin Psychiatry. 2022;35(6):417-424. PMID 36044299
  13. Storm MP, et al. Comparing treatments for post-traumatic stress disorder - a systematic review. Dan Med J. 2021;68(9):A09200643. PMID 34477098
  14. Markowitz JC Interpersonal Psychotherapy for Posttraumatic Stress Disorder: A Critical Review of the Evidence. J Clin Psychiatry. 2024;85(2):23nr15172. PMID 38814110
  15. Kline AC, et al. Long-term efficacy of psychotherapy for posttraumatic stress disorder: A meta-analysis of randomized controlled trials. Clin Psychol Rev. 2018;59:30-40. PMID 29169664
  16. Suomi A, et al. Couple and family therapies for post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2019;12(12):CD011257. PMID 31797352
  17. Tedstone JE, et al. Posttraumatic stress disorder following medical illness and treatment. Clin Psychol Rev. 2003;23(3):409-48. PMID 12729679
  18. Palmisano AN, et al. A systematic review evaluating PTSD treatment effects on intermediate phenotypes of PTSD. Psychol Trauma. 2024;16(5):768-783. PMID 36595460
  19. Henner RL, et al. Review of potential psychedelic treatments for PTSD. J Neurol Sci. 2022;439:120302. PMID 35700643
  20. Bisson J, et al. Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2005;(2):CD003388. PMID 15846661
  21. Sylvia AM, et al. Systematic Review of Dispositional Mindfulness and Posttraumatic Stress Disorder Symptomology: A Targeted Examination of Avoidance. Trauma Violence Abuse. 2024;25(4):2622-2637. PMID 38523454
  22. Bisson J, et al. Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2007;(3):CD003388. PMID 17636720
  23. Amsalem D, et al. Treatment dropout among veterans and their families: Quantitative and qualitative findings. Psychol Trauma. 2022;14(4):578-586. PMID 34582228
  24. Mavranezouli I, et al. Psychological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychol Med. 2020;50(4):542-555. PMID 32063234
  25. Lewis C, et al. Psychological therapies for post-traumatic stress disorder in adults: systematic review and meta-analysis. Eur J Psychotraumatol. 2020;11(1):1729633. PMID 32284821
  26. McLean CP, et al. Exposure therapy for PTSD: A meta-analysis. Clin Psychol Rev. 2022;91:102115. PMID 34954460
  27. Etingen B, et al. Drivers of Preference for Evidence-Based PTSD Treatment: A Qualitative Assessment. Mil Med. 2020;185(Suppl 1):303-310. PMID 32074319
  28. Monson CM, et al. Cognitive-behavioural conjoint therapy versus prolonged exposure for PTSD in military service members and veterans: results and lessons from a randomized controlled trial. Eur J Psychotraumatol. 2024;15(1):2330305. PMID 38590124
  29. Wright S, et al. Predictors of study dropout in cognitive-behavioural therapy with a trauma focus for post-traumatic stress disorder in adults: An individual participant data meta-analysis. BMJ Ment Health. 2024;27(1):e301159. PMID 39537555
  30. Maglione MA, et al. Effect of patient characteristics on posttraumatic stress disorder treatment retention among veterans: A systematic review. J Trauma Stress. 2022;35(2):718-728. PMID 34800059
  31. Hoppen TH, et al. The efficacy and acceptability of psychological interventions for adult PTSD: A network and pairwise meta-analysis of randomized controlled trials. J Consult Clin Psychol. 2023;91(8):445-461. PMID 37141033